Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

NCT05535361 is registered in ClinicalTrials.gov with Eclipse Regenesis, Inc. as lead sponsor.

NCT NCT05535361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
Lead sponsor
Eclipse Regenesis, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
September 15, 2023
Completion date
June 30, 2028
Enrollment
40 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

short bowel syndrome